Recently scientists discovered a novel dual-targeted peptide that blocks CD24/Siglec-10 and PD-1/PD-L1 interactions, and demonstrated that radiation therapy (RT) can recruit tumor immune cells and upregulate PD-L1 expression, while CD24/Siglec-10 blocking peptide (CSBP) could suppress PD-1/PD-L1 expression. The gene discussed is CD274; the disease is neoplasm.